First Nebraska Trust Co Acquires Shares of 7,172 AbbVie Inc. $ABBV

Key Points

• First Nebraska Trust Co. acquired 7,172 AbbVie shares during the second quarter, valued at approximately $1.8 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie exceeded quarterly expectations, reporting $3.65 in earnings per share and $16.99 billion in revenue, with revenue up 10.2% year over year. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• Analysts maintain a broadly positive view, with a consensus “Moderate Buy” rating and a $275.95 price target versus the stock’s reported $261.50 price. AbbVie also pays a quarterly dividend of $1.73, or $6.92 annually, yielding about 2.6%.

First Nebraska Trust Co bought a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,172 shares of the company's stock, valued at approximately $1,805,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp boosted its stake in AbbVie by 1.4% during the fourth quarter. State Street Corp now owns 80,940,931 shares of the company's stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC grew its holdings in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Bank of America Corp DE increased its stake in shares of AbbVie by 1.4% during the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company's stock valued at $5,900,617,000 after purchasing an additional 356,394 shares in the last quarter. Norges Bank purchased a new position in shares of AbbVie during the fourth quarter valued at approximately $5,865,055,000. Finally, Capital Research Global Investors lifted its holdings in shares of AbbVie by 0.7% during the fourth quarter. Capital Research Global Investors now owns 25,408,200 shares of the company's stock valued at $5,805,530,000 after purchasing an additional 177,370 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $261.50 on Thursday. The firm's 50 day moving average price is $254.23 and its 200-day moving average price is $229.67. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company has a market cap of $462.02 billion, a PE ratio of 73.87, a P/E/G ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The firm's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on ABBV shares. Weiss Ratings upgraded AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday, August 4th. Morgan Stanley reiterated an "overweight" rating and set a $296.00 price objective on shares of AbbVie in a research note on Monday, August 3rd. HSBC reissued a "buy" rating and issued a $300.00 target price on shares of AbbVie in a report on Monday, July 6th. Evercore set a $235.00 target price on AbbVie in a research note on Friday, May 15th. Finally, Cantor Fitzgerald raised their price target on AbbVie from $265.00 to $285.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $275.95.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source